Gruppo Italiano Malattie EMatologiche dell'Adulto

🇮🇹Italy
Ownership
Private
Employees
-
Market Cap
-
Website

Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
Conditions
First Posted Date
2023-09-07
Last Posted Date
2024-07-25
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
170
Registration Number
NCT06026644
Locations
🇮🇹

Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia, Bologna, Italy

🇮🇹

AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale, Firenze, Italy

🇮🇹

Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Ad Indirizzo Oncologico, Palermo, Italy

and more 10 locations

Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

Not yet recruiting
Conditions
First Posted Date
2023-09-07
Last Posted Date
2023-09-07
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
736
Registration Number
NCT06028087

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

First Posted Date
2023-09-06
Last Posted Date
2024-04-11
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
158
Registration Number
NCT06025682
Locations
🇮🇹

UOC Ematologia Fondazione Policlinico Universitario A.Gemelli, Roma, Italy

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

First Posted Date
2023-07-03
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
96
Registration Number
NCT05927558
Locations
🇮🇹

Ematologia Istituto Nazionale Tumori, Milano, Italy

Real World Evidence of Fedratinib Effectiveness in MF

First Posted Date
2023-06-01
Last Posted Date
2024-02-08
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
93
Registration Number
NCT05883904
Locations
🇮🇹

Ematologia FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO, Milano, Italy

Novel Approaches to Target MECOM/EVI1 in AML

Not Applicable
Recruiting
Conditions
First Posted Date
2023-05-03
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
24
Registration Number
NCT05839392
Locations
🇮🇹

Ematologia, Piacenza, Italy

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

First Posted Date
2023-04-07
Last Posted Date
2023-11-28
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
954
Registration Number
NCT05803395
Locations
🇮🇹

UOC Ematologia AO Cosenza, Cosenza, Italy

🇮🇹

Ematologia AOU S.Anna, Ferrara, Italy

🇮🇹

Ematologia AOU Careggi, Firenze, Italy

and more 12 locations

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

First Posted Date
2023-01-23
Last Posted Date
2023-12-01
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
45
Registration Number
NCT05694312
Locations
🇮🇹

Ematologia Osp Molinette, Torino, Italy

🇮🇹

Ematologia Osp Careggi, Firenze, Italy

🇮🇹

Ematologia Osp Maggiore della Carità, Novara, Italy

Biologic Characterization of Patients With ITP

First Posted Date
2023-01-23
Last Posted Date
2024-05-21
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
200
Registration Number
NCT05694325
Locations
🇮🇹

Sc Ematologia Ospedale S.G. Battista Molinette - Università Degli Studi Di Torino, Torino, Italy

🇮🇹

SC Ematologia ASUGI, Trieste, Italy

🇮🇹

Ematologia e centro trapianti ASL Piacenza, Piacenza, Italy

and more 2 locations

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

First Posted Date
2022-11-14
Last Posted Date
2023-01-13
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
47
Registration Number
NCT05613296
© Copyright 2024. All Rights Reserved by MedPath